{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-046812","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2024-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.318756+00:00","generated_at":"2026-05-29T22:41:34.828370+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"MIRA Pharmaceuticals selects CHDR for Phase I/IIa trial of Ketamir-2; recruitment starts Q1 2025","bullets":["Trial site: The Centre for Human Drug Research (CHDR) in Leiden, Netherlands.","Phase I in healthy subjects: initial safety/efficacy results expected H2 2025.","Phase IIa planned Q4 2025 in diabetic neuropathy patients; efficacy results in H1 2026.","Will use CHDR's PainCart® technology for early pain response measurement.","Psychoactivity assessed separately; trial leverages unique early-efficacy capability."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-046812","json":"https://secwatch.observer/filing/0001493152-24-046812.json","markdown":"https://secwatch.observer/filing/0001493152-24-046812.md","text":"https://secwatch.observer/filing/0001493152-24-046812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224046812/0001493152-24-046812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315224046812/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:41:34.828370+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}